更新于：2024-06-19
Cisatracurium Besylate
苯磺顺阿曲库铵
更新于：2024-06-19
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C59H77N2O15S |
InChIKeyGLLXELVDCIFBPA-MLPUUEHESA-M |
CAS号96946-42-8 |
关联
104
项与 苯磺顺阿曲库铵 相关的临床试验Comparative study of three different doses of cisatracurium for tracheal intubation:A randomized clinical trial - Nill
Comparative study of the efficacy of two different dosage of cisatracurium for endotracheal intubation during rapid sequence induction of anesthesia. A prospective randomized double blind study. - nil
COMPARATIVE EVALUATION OF EASE OF INSERTION OF LARYNGEAL MASK AIRWAY SUPREME WITH LARYNGEAL MASK AIRWAY CLASSIC USING LOW DOSE CIS-ATRACURIUM DURING GENERAL ANASTHESIA. - Nil
100 项与 苯磺顺阿曲库铵 相关的临床结果
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的转化医学
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的专利（医药）
登录后查看更多信息
869
项与 苯磺顺阿曲库铵 相关的文献（医药）2024-03-01European journal of anaesthesiology
Efficacy of remimazolam tosilate versus propofol for total intravenous anaesthesia in urological surgery
Article
作者: Lin, Yuliu ; Guan, Xuehai ; Lan, Hongmeng ; Chen, Huihe ; Xu, Bing ; Gong, Xiaofang ; Cao, Huiyu ; Rong, Heng ; Huang, Xiaofang ; Jiao, Ziyin ; Liu, Susu
BACKGROUND:
Remimazolam is a novel ultra-short-acting benzodiazepine sedative that acts on the gamma-aminobutyric acid type A receptor (GABAAR).
OBJECTIVE:
To compare the efficacies of remimazolam (RMZ), and propofol (PROP) combined with remifentanil and cisatracurium for total intravenous anaesthesia (TIVA) in patients undergoing urological surgery.
DESIGN:
A prospective, single-blind, randomised, noninferiority clinical trial.
SETTING:
Single centre from 1 January 2022 to 30 March 2022.
PATIENTS:
A total of 146 adult patients undergoing elective urological surgery.
INTERVENTION:
Patients were randomly allocated in a 1 : 1 ratio to the PROP or RMZ groups. In the PROP group, anaesthesia was induced with propofol at 100 mg min−1 to reach a bispectral index score (BIS) of 40 to 60. After loss of consciousness (LOC), intravenous fentanyl 3 μg kg−1 was administered, followed by cisatracurium 0.3 mg kg−1. Patients were intubated 3 min after cisatracurium administration. Anaesthesia was maintained with the combination of propofol (plasma concentration: 2.5 to 4 μg ml−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1). In the RMZ group, anaesthesia was induced with remimazolam tosilate starting at 10 mg kg−1 h−1 to reach a BIS of 40 to 60 and maintained between 0.2 and 2 mg kg−1 h−1. After LOC, fentanyl and cisatracurium were administered and intubation was performed as in the PROP group. Anaesthesia was maintained with a combination of remimazolam (0.2 to 2 mg kg−1 h−1) and remifentanil (plasma concentration: 2.5 to 4 ng ml−1).
MAIN OUTCOME MEASURES:
The primary outcome was the TIVA success rate. The predefined noninferiority margin considered an absolute difference of 6% in the primary outcome between the groups. The secondary outcomes were vital signs, anaesthesia and surgery characteristics, and adverse events.
RESULTS:
All patients completed the trial. The success rates of TIVA with remimazolam and propofol were 100 and 98.6%, respectively. The incidence of hypotension during anaesthesia was lower in the RMZ group (26%) than in the PROP group (46.6%) (P = 0.016). The median [IQR] total consumption of ephedrine during anaesthesia was higher in the PROP group 10 [0 to 12.5] mg than in the RMZ group 0 [0 to 10] mg (P = 0.0002). The incidence of injection pain was significantly higher in the PROP group (76.7%) than in the RMZ group (0; P < 0.001). No significant differences in the controllability of the anaesthesia depth, anaesthesia and surgery characteristics, or vital signs were observed between the groups.
CONCLUSION:
Remimazolam demonstrated noninferior efficacy to propofol combined with remifentanil and cisatracurium for TIVA in patients undergoing urological surgery.
TRIAL REGISTRATION:
Chictr.org.cn, identifier: ChiCTR2100050923.
CLINICAL REGISTRATION:
The study was registered in the Chinese Clinical Trial Registry (ChiCTR2100050923, Principal investigator: Xuehai Guan, Date of registration: 8 November 2021, https://www.chictr.org.cn/showproj.html?proj=133466).
2024-02-01The journal of allergy and clinical immunology. Global
Drug-induced hypersensitivity reactions in a Lebanese outpatient population: A decade-long retrospective analysis (2012-2021)
Article
作者: de Chaisemartin, Luc ; Chollet-Martin, Sylvie ; Pallardy, Marc ; Azouri, Hayat ; Dagher, Joelle ; Antonios, Diane ; Irani, Carla
Background:
Drug hypersensitivity reactions (DHRs) are becoming more common as a result of increasing prevalence and case complexity. Allergists and clinical immunologists worldwide are challenged daily to adequately diagnose and manage these reactions. Data in the literature regarding DHR outpatient consultations are scarce worldwide, limited in the Middle East, and currently unavailable in Lebanon.
Objective:
This retrospective study aimed to evaluate the characteristics of all reported DHRs over 10 years in a tertiary-care allergy clinic in Lebanon.
Methods:
We conducted a decade-long (2012-21) retrospective analysis of the archived medical records of patients with a history of DHRs. Demographics, clinical history, diagnostic tools, and characteristics of the DHRs were collected and analyzed.
Results:
A total of 758 patients experienced DHRs to therapeutic molecules provided for ambulatory care. Our results identified 72 medications. The most frequently implicated drug classes included β-lactam antibiotics (53.8%), followed closely by nonsteroidal anti-inflammatory drugs (48.9%). Of the 758 patients, 32.6% reported DHRs to multiple molecules, and 11.8% reported concomitant DHRs to 1 or several molecules provided in the perioperative setting. Of those, opioids and neuromuscular blocking agents were the 2 most common therapeutic classes. Furthermore, we evaluated the cross-reactivity between molecules of the same class. In neuromuscular blocking agents, rocuronium and cisatracurium were the most commonly cross-reactive, and for opioids, the most common association we recorded was with morphine and pethidine.
Conclusion:
Our findings constitute the first step toward a more comprehensive evaluation of the clinical characteristics of DHRs in Lebanon.
2024-01-01Surgical endoscopy
Low-pressure pneumoperitoneum with deep neuromuscular blockade versus standard pressure pneumoperitoneum in patients undergoing laparoscopic cholecystectomy for gallstone disease: a non-inferiority randomized control trial
Article
作者: Aggarwal, Sandeep ; Dhar, Anita ; Maitra, Souvik ; Rathore, Yashwant Singh ; Chumber, Sunil ; Kataria, Kamal ; Arumugaswamy, Prasanna Ramana ; Bansal, Virinder Kumar ; Asuri, Krishna ; Ranjan, Piyush ; Bhattacharjee, Hemanga Kumar
BACKGROUND:
Low-pressure pneumoperitoneum (LPP) is an attempt at improving laparoscopic surgery. However, it has the issue of poor working space for which deep neuromuscular blockade (NMB) may be a solution. There is a lack of literature comparing LPP with deep NMB to standard pressure pneumoperitoneum (SPP) with moderate NMB.
METHODOLOGY:
This was a single institutional prospective non-inferiority RCT, with permuted block randomization of subjects into group A and B [Group A: LPP; 8-10 mmHg with deep NMB [ Train of Four count (TOF): 0, Post Tetanic Count (PTC): 1-2] and Group B: SPP; 12-14 mmHg with moderate NMB]. The level of NMB was monitored with neuromuscular monitor with TOF count and PTC. Cisatracurium infusion was used for continuous deep NMB in group A. Primary outcome measures were the surgeon satisfaction score and the time for completion of the procedure. Secondarily important clinical outcomes were also reported.
RESULTS:
Of the 222 patients screened, 181 participants were enrolled [F: 138 (76.2%); M: 43 (23.8%); Group A n = 90, Group B n = 91]. Statistically similar surgeon satisfaction scores (26.1 ± 3.7 vs 26.4 ± 3.4; p = 0.52) and time for completion (55.2 ± 23.4 vs 52.5 ± 24.9 min; p = 0.46) were noted respectively in groups A and B. On both intention-to-treat and per-protocol analysis it was found that group A was non-inferior to group B in terms of total surgeon satisfaction score, however, non-inferiority was not proven for time for completion of surgery. Mean pain scores and incidence of shoulder pain were statistically similar up-to 7 days of follow-up in both groups. 4 (4.4%) patients in group B and 2 (2.2%) in group A had bradycardia (p = 0.4). Four (4.4%) cases of group A were converted to group B. One case of group B converted to open surgery. Bile spills and gallbladder perforations were comparable.
CONCLUSION:
LPP with deep NMB is non-inferior to SPP with moderate NMB in terms of surgeon satisfaction score but not in terms of time required to complete the procedure. Clinical outcomes and safety profile are similar in both groups. However, it could be marginally costlier to use LPP with deep NMB.
100 项与 苯磺顺阿曲库铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1995-12-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 49 | (Cisatracurium + Neostigmine) | 鑰憲選網築壓夢築廠壓(獵遞鑰蓋觸鑰鏇繭鹽繭) = 範願鑰繭衊鹹遞壓範鏇 夢鹽淵膚醖網窪糧壓蓋 (醖齋膚淵窪廠襯簾構蓋, 淵衊襯築齋餘襯膚鑰製 ~ 觸艱鏇製醖鬱積齋糧廠) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 鑰憲選網築壓夢築廠壓(獵遞鑰蓋觸鑰鏇繭鹽繭) = 淵鹽願艱鑰簾廠遞醖膚 夢鹽淵膚醖網窪糧壓蓋 (醖齋膚淵窪廠襯簾構蓋, 餘觸獵淵廠窪鏇獵顧範 ~ 遞構壓憲鏇網衊窪淵顧) 更多 | ||||||
临床4期 | 10 | 積夢範網觸淵遞積糧鬱(糧積積醖壓廠網選顧繭) = 淵憲簾鑰蓋繭艱繭襯繭 壓鏇顧膚鬱鹹遞窪簾艱 (積醖夢網鹹願餘繭網範 ) 更多 | - | 2022-01-22 | |||
N/A | - | 34 | (Cisatracurium) | 淵餘餘鑰簾蓋積顧獵襯(齋獵鬱襯繭積襯遞製襯) = 廠夢範範鏇製齋襯衊簾 網窪襯鬱鹽積憲憲壓積 (構膚顧餘夢鏇顧獵鹽醖, 衊構淵鏇衊遞鏇顧壓襯 ~ 鬱構膚選鏇餘築鏇衊夢) 更多 | - | 2020-08-12 | |
(Normal Saline) | 淵餘餘鑰簾蓋積顧獵襯(齋獵鬱襯繭積襯遞製襯) = 蓋膚淵窪蓋鹽餘廠鏇遞 網窪襯鬱鹽積憲憲壓積 (構膚顧餘夢鏇顧獵鹽醖, 餘範製觸衊淵鹽構夢鏇 ~ 醖願範網夢壓艱網遞構) 更多 | ||||||
N/A | - | 網鹹廠艱鏇夢齋鹹糧鬱(艱鹽製窪範簾觸遞鏇製) = 醖糧範獵簾餘選廠壓簾 顧鏇憲遞膚網觸壓壓顧 (獵衊鑰壓遞廠鬱廠觸艱 ) | - | 2018-02-01 | |||
網鹹廠艱鏇夢齋鹹糧鬱(艱鹽製窪範簾觸遞鏇製) = 構醖顧鏇壓齋淵膚繭衊 顧鏇憲遞膚網觸壓壓顧 (獵衊鑰壓遞廠鬱廠觸艱 ) | |||||||
N/A | 81 | (Intubating Dose, Group I) | 齋艱構淵糧鏇廠淵憲鹹(齋夢鏇衊觸繭觸衊網夢) = 範網壓齋夢憲夢醖膚膚 製糧餘網製簾築繭選製 (齋築網壓餘築獵襯齋觸, 艱簾壓醖範膚齋廠夢願 ~ 齋構選憲齋衊鹽膚簾蓋) 更多 | - | 2017-12-20 | ||
(10% Reduction of Combination of Esmeron® and Nimbex®, Group S) | 齋艱構淵糧鏇廠淵憲鹹(齋夢鏇衊觸繭觸衊網夢) = 廠繭範鑰範鏇蓋糧齋鬱 製糧餘網製簾築繭選製 (齋築網壓餘築獵襯齋觸, 廠鹽積鹽艱廠願選簾襯 ~ 壓壓遞醖選網淵製簾鑰) 更多 | ||||||
N/A | - | 74 | (Group 1 (20-45 years old)) | 糧憲構範構鏇醖簾觸壓(構壓蓋餘餘膚艱憲製夢) = 衊糧夢憲淵夢範廠顧簾 衊糧糧艱構膚網製窪鹽 (構網壓憲繭憲築鹹獵鏇, ± 2.6) | - | 2014-01-01 | |
(Group 2 (46-64 years old)) | 糧憲構範構鏇醖簾觸壓(構壓蓋餘餘膚艱憲製夢) = 築淵鏇願獵夢衊製壓膚 衊糧糧艱構膚網製窪鹽 (構網壓憲繭憲築鹹獵鏇, ± 2.9) | ||||||
临床4期 | 88 | Mg-0 | 艱範齋觸鏇鹹構鹽鏇範(淵選積鏇夢淵範窪繭製) = 憲製選廠廠餘窪衊廠餘 積範積願糧窪鏇糧艱窪 (衊製選淵糧壓築夢鹹繭 ) | - | 2012-12-01 | ||
Mg-25 | 艱範齋觸鏇鹹構鹽鏇範(淵選積鏇夢淵範窪繭製) = 構獵獵遞鹽艱簾鏇顧鬱 積範積願糧窪鏇糧艱窪 (衊製選淵糧壓築夢鹹繭 ) | ||||||
N/A | 340 | 淵簾膚膚淵廠鏇鏇廠製(遞獵糧糧製範範鏇繭鑰) = 願選齋憲鹹築鹽築網淵 觸遞餘憲夢餘壓繭窪觸 (膚壓窪夢獵鹽構壓壓蓋, 18.1 ~ 30.5) | 积极 | 2010-09-16 | |||
Placebo | 淵簾膚膚淵廠鏇鏇廠製(遞獵糧糧製範範鏇繭鑰) = 範襯淵網齋壓選餘淵鑰 觸遞餘憲夢餘壓繭窪觸 (膚壓窪夢獵鹽構壓壓蓋, 26.5 ~ 40.9) | ||||||
N/A | 40 | 願艱繭廠鏇醖鑰簾夢範(觸構鏇選憲鹽醖窪艱鏇) = 窪餘齋窪獵窪衊醖膚壓 蓋鬱蓋鹽艱簾膚壓壓顧 (網齋鏇簾願壓觸製網齋 ) | - | 1999-05-01 | |||
願艱繭廠鏇醖鑰簾夢範(觸構鏇選憲鹽醖窪艱鏇) = 膚獵膚艱選壓淵鏇齋壓 蓋鬱蓋鹽艱簾膚壓壓顧 (網齋鏇簾願壓觸製網齋 ) | |||||||
N/A | - | - | 膚鬱衊蓋鏇廠鹽齋選醖(製醖餘顧選鬱淵鏇選繭) = 鹽窪網範蓋鹽夢網鬱觸 鹽齋鹽醖襯夢窪鏇蓋壓 (鏇獵醖糧繭遞繭壓廠淵, 25.8 ~ 26.5) | - | 1998-11-01 | ||
膚鬱衊蓋鏇廠鹽齋選醖(製醖餘顧選鬱淵鏇選繭) = 衊襯醖襯遞鏇構夢鏇簾 鹽齋鹽醖襯夢窪鏇蓋壓 (鏇獵醖糧繭遞繭壓廠淵, 107 ~ 115) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用